Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Year: 2019
Type: article
Source: Gastroenterology
Institutions: University of California San Diego, Centre Hospitalier Régional et Universitaire de Nancy, Université de Lorraine, Humanitas University, Universitair Ziekenhuis Leuven, Icahn School of Medicine at Mount Sinai, Agaplesion Markus Hospital, Hebrew University of Jerusalem, Shaare Zedek Medical Center, Bikur Cholim Hospital, Goethe University Frankfurt, Mines Saint-Étienne, Inserm, Université Paris Diderot, Dartmouth–Hitchcock Medical Center, University of Vienna, Medical University of Vienna
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Boehringer Ingelheim, Abbott Laboratories, Falk Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Merck, Roche, Gilead Sciences, Biogen, Celgene, AbbVie, Meso Scale Diagnostics, Schering-Plough, Takeda Pharmaceuticals U.S.A., Ipsen Biopharmaceuticals, Hospira, Arrien Pharmaceuticals, Seres Therapeutics, Shire, MedImmune, Ferring Pharmaceuticals, Angelini Pharma, Menarini Group, Dr. Falk Pharma, Atlantic Healthcare, Sandoz, School of Public Health, University of California Berkeley, Janssen Pharmaceuticals
OpenAlex ID: W2949271110
